HCID 23498817, Verbindung → 3-[1-{3-[3-(3,5-Dimethyl-piperazin-1-yl)-3-oxo-propyl]-4,5,6,7-tetrahydro-1h-indol-2-yl}-meth-(z)-ylidene]-5-ethanesulfonyl-1,3-dihydro-indol-2-one
Reaktionsgleichung
[CH3:1][CH:2]1[NH:7][CH:6]([CH3:8])[CH2:5][N:4]([C:9](=[O:23])[CH2:10][CH2:11][C:12]2[C:20]3[CH2:19][CH2:18][CH2:17][CH2:16][C:15]=3[NH:14][C:13]=2[CH:21]=O)[CH2:3]1.[CH2:24]([S:26]([C:29]1[CH:30]=[C:31]2[C:35](=[CH:36][CH:37]=1)[NH:34][C:33](=[O:38])[CH2:32]2)(=[O:28])=[O:27])[CH3:25]>>[CH3:1][CH:2]1[NH:7][CH:6]([CH3:8])[CH2:5][N:4]([C:9](=[O:23])[CH2:10][CH2:11][C:12]2[C:20]3[CH2:19][CH2:18][CH2:17][CH2:16][C:15]=3[NH:14][C:13]=2/[CH:21]=[C:32]2\[C:33](=[O:38])[NH:34][C:35]3[C:31]\2=[CH:30][C:29]([S:26]([CH2:24][CH3:25])(=[O:27])=[O:28])=[CH:37][CH:36]=3)[CH2:3]1Komponenten
3
Versuchsvorschrift
3-[3-(3,5-Dimethylpiperazin-1-yl)-3-oxo-propyl]-4,5,6,7-tetrahydro-1H-indole-2-carbaldehyde, prepared as described in Example 3 above, was condensed with 5-ethylsulfonyloxindole following the same procedure used in example 1 to give the desired product (72 mg, 46% yield).